VistaGen Therapeutics Inc. (NASDAQ:VTGN) is pioneering a new generation of fast-acting, non-sedating, non-addictive medications targeting mental health conditions like social anxiety disorder, major depressive disorder, postpartum depression, and adjustment disorder. The company's pipeline includes innovative drugs that modulate the NMDA receptor and activate the neurokinin-1 receptor — mechanisms with the potential to shift paradigms in psychiatry.
